Additional file 1: of Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer

Effect of 30 day treatment with 40 mg/kg TQ or vehicle in NGL reporter mice injected with ID8 cells. (A) Quantification of ascites fluid volume at sacrifice showed increased ascites with TQ treatment, but no significant differences in (B) the number of peritoneal implants or (C) mesenteric tumor mass. (D) QPCR analysis of the mRNA expression of the markers of M2 macrophages, mannose-receptor (mann-R) and interleukin-10 (IL-10) and M1 macrophages (CCL3) in RNA extracted from peritoneal lavages or ascites fluid. Values were normalized to corresponding levels of GAPDH mRNA expression. (E) Luciferase activity of the NF-ÎşB reporter was measured in isolated macrophages from ascites or peritoneal lavage fluid, and expressed relative to cellular protein. Values are mean+SD for 5 mice per group. *p < 0.01 relative to vehicle-treated mice; NS: not significant relative to vehicle, Mann-Whitney test. (PDF 117 kb

Clinical characteristics and ABO blood type among Tumor Registry Confirmed ovarian cancer cases from VUMC EMR.

<p>Clinical characteristics and ABO blood type among Tumor Registry Confirmed ovarian cancer cases from VUMC EMR.</p

Blood type, ABO genetic variants, and ovarian cancer survival

<div><p>Objective</p><p>Blood type A and the A1 allele have been associated with increased ovarian cancer risk. With only two small studies published to date, evidence for an association between ABO blood type and ovarian cancer survival is limited.</p><p>Methods</p><p>We conducted a retrospective cohort study of Tumor Registry confirmed ovarian cancer cases from the Vanderbilt University Medical Center with blood type from linked laboratory reports and ABO variants from linked Illumina Exome BeadChip data. Associations with overall survival (OS) were quantified by hazard ratios (HR) and confidence intervals (CI) from proportional hazards regression models; covariates included age, race, stage, grade, histologic subtype, and year of diagnosis.</p><p>Results</p><p>ABO phenotype (N = 694) and/or genotype (N = 154) data were available for 713 predominantly Caucasian (89.3%) cases. In multivariable models, blood type A had significantly better OS compared to either O (HR: 0.75, 95% CI: 0.60–0.93) or all non-A (HR: 0.77, 95% CI: 0.63–0.94) cases. Similarly, missense rs1053878 minor allele carriers (A2) had better OS (HR: 0.50, 95% CI: 0.25–0.99). Among Caucasians, this phenotype association was strengthened, but the genotype association was attenuated; instead, four variants sharing moderate linkage disequilibrium with the O variant were associated with better OS (HR: 0.62, 95% CI: 0.39–0.99) in unadjusted models.</p><p>Conclusions</p><p>Blood type A was significantly associated with longer ovarian cancer survival in the largest such study to date. This finding was supported by genetic analysis, which implicated the A2 allele, although O related variants also had suggestive associations. Further research on ABO and ovarian cancer survival is warranted.</p></div

ABO blood type and overall ovarian cancer survival among Tumor Registry Confirmed cases from VUMC EMR.

<p>ABO blood type and overall ovarian cancer survival among Tumor Registry Confirmed cases from VUMC EMR.</p

Common ABO variants and overall ovarian cancer survival among Tumor Registry Confirmed cases from VUMC EMR.

<p>Common ABO variants and overall ovarian cancer survival among Tumor Registry Confirmed cases from VUMC EMR.</p

Additional file 3: of Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors

COX Expression: Correlation between QPCR and IHC. Pearson correlations between COX expression levels measured by quantitative PCR and H-scores from IHC. (PPTX 235 kb

Common ABO variants evaluated and phenotype and related information.

<p>Common ABO variants evaluated and phenotype and related information.</p

Kaplan-Meier survival functions for overall ovarian cancer survival.

<p>A) Blood type A vs all other types among all cases with blood type from linked EMR; 1B) Minor allele carriers of rs1053878 (A2) vs non-minor allele carriers among all genotyped cases; 1C) Minor allele carriers of rs549446 (r²>0.2 with rs505922) vs non-minor allele carriers among genotyped Caucasian cases; X-axis = years of Overall Survival; Y-axis = Percent of Cases Alive.</p

Additional file 1: of Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors

Characterization of new rabbit polyclonal anti-COX-1. A) Protein sequences of human COX-1 and COX-2 show that peptides used in anti-COX-1 generation (shaded in yellow) had no overlap with the corresponding COX-2 sequence. B) Western blot analysis using the newly generated Vanderbilt anti-COX-1 (1:2000 overnight) show detection of COX-1 at the expected molecular weight (approximately 68 kDa). COX-2 was detected by rabbit polyclonal anti-COX-2. Actin was used as loading control. Samples used were COX-1-expressing OVCAR-3 cell lysate, COX-2-expressing 4 T1 cell lysate, recombinant ovine COX-1 and recombinant human COX-2. (PPTX 71 kb

Additional file 2: of Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors

COX-1 expression in ovarian cancer measured by the commercial Santa Cruz antibody (IHC). A) Pearson correlation between IHC expression levels of COX-1 and COX-2. H-scores for COX-1 expression in B) serous, endometrioid, mucinous and clear cell tumors, and in C) serous tumors versus all other epithelial tumors, and type II versus type I tumors. P values were determined by Student’s t-test. (PPTX 377 kb